20 Lymphoma Clinical Trials in Los Angeles, CA (2026)

Q: How do I join a clinical trial in Los Angeles?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you.

Recruiting Lymphoma Studies in Los Angeles

NCT06717347Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment ...

Los Angeles, CAPHASE31,046 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06091865Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Ly...

Los Angeles, CAPHASE3904 participantsRegeneron Pharmaceuticals

View Study Details

NCT06091254Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin...

Los Angeles, CAPHASE3822 participantsRegeneron Pharmaceuticals

View Study Details

NCT06149286Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of canc...

Los Angeles, CAPHASE3470 participantsRegeneron Pharmaceuticals

View Study Details

NCT07226843Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously t...

Los Angeles, CAPHASE1460 participantsEli Lilly and Company

View Study Details

NCT05976763Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who ha...

Los Angeles, CAPHASE3421 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT07188558Recruiting

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or ref...

Los Angeles, CAPHASE3400 participantsLyell Immunopharma, Inc.

View Study Details

NCT05826535Recruiting

Study of LYL314 in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 ...

Los Angeles, CAPHASE1270 participantsLyell Immunopharma, Inc.

View Study Details

NCT06500273Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable f...

Los Angeles, CAPHASE2250 participantsAllogene Therapeutics

View Study Details

NCT05890352Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating pat...

Los Angeles, CAPHASE2227 participantsSWOG Cancer Research Network

View Study Details

NCT04329728Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) ...

Los Angeles, CAPHASE1144 participantsAVM Biotechnology Inc

View Study Details

NCT07691606Recruiting

A Study of ARC-02 in B-cell NHL

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02....

Los Angeles, CAPHASE1140 participantsTaiho Oncology, Inc.

View Study Details

NCT06649812Recruiting

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-g...

Los Angeles, CAPHASE2120 participantsNational Cancer Institute (NCI)

View Study Details

NCT06806033Recruiting

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitam...

Los Angeles, CAPHASE2100 participantsHoffmann-La Roche

View Study Details

NCT06634589Recruiting

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed...

Los Angeles, CAPHASE180 participantsBeiGene

View Study Details

NCT05237986Recruiting

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about ...

Los Angeles, CA60 participantsNational Cancer Institute (NCI)

View Study Details

NCT04609046Recruiting

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central...

Los Angeles, CAPHASE147 participantsNational Cancer Institute (NCI)

View Study Details

NCT04234048Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

Los Angeles, CAPHASE146 participantsSciTech Development, Inc.

View Study Details

NCT06252675Recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improve...

Los Angeles, CAPHASE230 participantsUniversity of California, San Francisco

View Study Details

NCT05256641Recruiting

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer com...

Los Angeles, CAPHASE124 participantsJonsson Comprehensive Cancer Center

View Study Details

About Lymphoma Clinical Trials in Los Angeles

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 20 lymphoma clinical trials recruiting participants in Los Angeles, CA. These studies are seeking a combined 6,061 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals, Eli Lilly and Company and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Los Angeles — FAQ

Are there lymphoma clinical trials in Los Angeles?

Yes, there are 20 lymphoma clinical trials currently recruiting in Los Angeles, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 20 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 16, 2026 from ClinicalTrials.gov